Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

Blood

Volumn 118, Issue 2, 2011, Pages 276-281

  Treon, Steven P ^a   Soumerai, Jacob D ^a   Hunter, Zachary R ^a   Patterson, Christopher J ^a   Ioakimidis, Leukothea ^a   Kahl, Brad ^b   Boxer, Michael ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BORTEZOMIB; CIMETIDINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; DIPHENHYDRAMINE; DOXORUBICIN; FAMCICLOVIR; GANCICLOVIR; HYDROCORTISONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; SULFAMETHOXAZOLE; THALIDOMIDE; TRIMETHOPRIM; VALGANCICLOVIR; VINCRISTINE SULFATE;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ALLERGY; ANEMIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; BACKACHE; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG FEVER; DYSPEPSIA; DYSPNEA; EDEMA; ESOPHAGUS CANDIDIASIS; FATIGUE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MYALGIA; MYASTHENIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RASH; REFRACTORY PERIOD; SIDE EFFECT; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79960463541     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-338558     Document Type: Article

References (34)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115. (Pubitemid 36506291)
2. Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:194-195.
3. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood. 2009;114(12):2375-2385.
4. Treon SP, Merlini G. Macroglobulinemia. In:Williams Hematology . 8th ed. New York: McGraw Hill; 2010:1695-1708.
5. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother. 2001;24(3):272-279. (Pubitemid 32479719)
6. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45(10):2047-2055. (Pubitemid 39232853)
7. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol. 2002;20(9):2327-2333.
8. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005;16(1):132-138. (Pubitemid 40124490)
9. Furman RR, Eradat H, Switzky JC, et al. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 1795.
10. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004;15(10):1481-1483. (Pubitemid 39409737)
11. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101(11):2593-2598. (Pubitemid 39532289)
12. Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(26):6325-6332. (Pubitemid 46218842)
13. Ravandi F, O'Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest. 2006;24(7):718-725. (Pubitemid 44836176)
14. Treon SP, Kelliher A, Keele B, et al. Expression of serotherapy target antigens in Waldenström's Macroglobulinemia: therapeutic applications and considerations. Semin Oncol. 2003;30(2):248-252. (Pubitemid 36506319)
15. Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom's macroglobulinemia: Implications for alemtuzumab therapy and response assessment. Clin Lymph. 2005;5(4):278-281. (Pubitemid 40614243)
16. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006;12(23):7174-7179. (Pubitemid 44974519)
17. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-3849.
18. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's Macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006;17(8):1275-1282. (Pubitemid 44288218)
19. Santos DD, Hatjiharissi E, Tournilhac O, et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's macroglobulinemia and mast cell disorders. Clin Lymph Myeloma. 2006;6(6):478-483.
20. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol. 2003;30(2):116-120.
21. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6(5):380-383.
22. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood. 2009;113(16):3673-3678.
23. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112(16):4452-4457.
24. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554-3561. (Pubitemid 34534522)
25. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100(3):768-773. (Pubitemid 34832599)
26. Owen RG, Rawstron AC, Osterborg A, et al. Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia [abstract]. Blood. 2003;102(11):2380.
27. Li J, Sze DM, Brown RD, Cowley MJ, et al. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood. 2010;115(17):3580-3588.
28. Jiang J, Yang G, Liu X, et al, et al. Microarray analysis of the peripheral monocytes from Waldenstrom's macroglobulinemia patients reveals a distinct gene expression profile [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 2010.
29. Ambrose LR, Morel AS, Warrens WN. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood. 2009;114(14):3052-3055.
30. Doubek M, Korístek Z, Havranova D, et al. Megakaryocyte colony-forming unit growth is enhanced by alemtuzumab: in vitro experiments and a case report of acquired amegakaryocytic thrombocytopenic purpura. Leukemia. 2006;20(9):1618-1620.
31. Otton SH, Turner DL, Frewin R, et al. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukemia. Br J Haematol. 1999;106(1):261-262. (Pubitemid 29343567)
32. Hertenstein B, Wagner B, Bunjes D, et al. Emergence of CD52-, phosphotidylinositolglycan-anchor-deficient T-lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood. 1995;86(4):1487-1492.
33. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98(4):773-778. (Pubitemid 36959274)
34. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab therapy. Blood. 2008;111(4):1816-1819. (Pubitemid 351451487)